sonelokimab

Ask MedXY AI

Latest news

Tag

Allergy & Immunologyclinical trialhidradenitis suppurativa

Sonelokimab: A Promising Dual IL-17A/F Nanobody for Moderate-to-Severe Hidradenitis Suppurativa

By MedXY|Oct 16, 2026

The phase 2 MIRA trial shows sonelokimab, an IL-17A/F-inhibiting nanobody, significantly improves outcomes in moderate-to-severe hidradenitis suppurativa with good tolerability compared to placebo.

Dermatologybiologicspsoriatic arthritis

Dual IL‑17A/IL‑17F blockade with sonelokimab produces robust clinical responses in active psoriatic arthritis: phase 2 randomized trial

By MedXY|Nov 12, 2025

A phase 2 randomized, placebo‑controlled trial found sonelokimab — a nanobody that inhibits IL‑17A and IL‑17F — produced significant improvements in joint and skin outcomes in active psoriatic arthritis versus placebo, with an acceptable sh